{"schema_version":"secwatch.filing_event.v1","accession":"0000075252-23-000004","form_type":"8-K","ticker":"ACH","cik":"0000075252","company_name":"ACCENDRA HEALTH INC/VA/","filed_at":"2023-02-28T23:59:59+00:00","discovered_at":"2026-05-14T18:03:47.982677+00:00","generated_at":"2026-06-18T22:57:25.511737+00:00","sec_items":["2.02","7.01","8.01","9.01"],"event_type":"earnings","sentiment":"negative","materiality_score":0.8,"calibrated_materiality_score":0.8,"confidence":"high","headline":"Owens & Minor reports Q4 GAAP operating loss of $53.5M; launches cost-cutting program targeting $200M by 2025","bullets":["Q4 revenue $2,551M, up 3.4% YoY; full-year revenue $9,955M, up 1.7%.","Q4 GAAP net loss $58.0M ($0.77 loss per share); adjusted net income $21.7M ($0.28 per share).","Patient Direct Q4 revenue up 135% (10.3% adjusted for Apria); full-year operating cash flow $325M.","Operating Model Realignment Program targets $30M adjusted operating income in 2023, $200M by 2025, and $250-400M working capital benefit.","Perry Bernocchi promoted to CEO of Patient Direct segment; Dan Starck named EVP Business Excellence, both effective March 1, 2023."],"urls":{"canonical":"https://secwatch.observer/filing/0000075252-23-000004","json":"https://secwatch.observer/filing/0000075252-23-000004.json","markdown":"https://secwatch.observer/filing/0000075252-23-000004.md","text":"https://secwatch.observer/filing/0000075252-23-000004.txt","edgar_index":"https://www.sec.gov/Archives/edgar/data/75252/000007525223000004/0000075252-23-000004-index.htm","edgar_primary_document":"https://www.sec.gov/Archives/edgar/data/75252/000007525223000004/omi-20230228.htm"},"model":{"generated_by":"deepseek-v4-flash:cloud@v2","generated_at":"2026-06-18T22:57:25.511737+00:00"},"review":{"review_status":"machine_generated","human_reviewed":false,"corrected":false,"correction_note":null,"correction_timestamp":null,"superseded_by":null,"related_filings":[]},"source_grounded_claims":[{"claim_id":"6fed71a9b5dde7a57c4814ff540f0c2b76e6bdb8","claim":"ACCENDRA HEALTH INC/VA/ reported the year ended December 31, 2022 results: revenue $9,955, net income $22.4, EPS $0.29.","evidence_excerpt":"Financial Summary (1) FYE FYE ($ in millions, except per share data) 4Q22 4Q21 2022 2021 Revenue $2,551 $2,467 $9,955 $9,785 Operating (loss) income, GAAP $(53.5) $62.0 $142.9 $368.5 Adj. Operating Income, Non-GAAP $67.2 $84.9 $369.1 $442.4 Net (loss) income, GAAP $(58.0) $42.0 $22.4 $221.6 Adj. Net Income, Non-GAAP $21.7 $61.2 $184.2 $309.3 Adj. EBITDA, Non-GAAP $116.7 $97.4 $517.8 $492.3 Net (loss) income per common share, GAAP $(0.77) $0.55 $0.29 $2.94 Adj. Net Income per share, Non-GAAP (2) $0.28 $0.81 $2.42 $4.10","evidence_source":"SEC 8-K Item 2.02","evidence_url":"https://www.sec.gov/Archives/edgar/data/75252/000007525223000004/0000075252-23-000004-index.htm","confidence":0.9,"family_label":"Earnings Releases","details":[{"label":"Period","value":"the year ended December 31, 2022"},{"label":"Revenue","value":"$9,955"},{"label":"Net income","value":"$22.4"},{"label":"EPS","value":"$0.29"},{"label":"Result","value":"reported results"}],"fact_type":"earnings_release"}],"license":"Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer"}